Table 1: Demographic and clinical characteristics of the study population, according to development of CIN.
Male,n(%) |
182(77.1%) |
41(64.1%) |
0.010 |
Age, (years) |
63.1±11.2 |
64.8±9.5 |
0.141 |
BMI,(Kg/m2) |
24.2±2.9 |
24.4±3.3 |
0.333 |
Hypertension,n(%) |
122(51.7%) |
33(51.6%) |
0.110 |
Diabetes,n (%) |
29(12.3%) |
15(23.4%) |
0.010 |
Stroke,n (%) |
21(8.90%) |
7(10.9%) |
0.160 |
Emergent intervention,n (%) |
52(22.0%) |
22(34.4%) |
0.020 |
Heart failure,n (%) |
154(65.3%) |
49(76.6%) |
0.030 |
Multivessel lesion,n (%) |
183(77.5%) |
55(85.9%) |
0.050 |
Hematocrit,n (%) |
41.0±6.5 |
40.2±6.6 |
0.194 |
Contrast agent dose, (ml) |
126.8±61.9 |
131.3±60.6 |
0.305 |
Rehydration therapy,n (%) |
185(78.4%) |
43(67.2%) |
0.020 |
Albumin,(g/L) |
40.3±3.8 |
38.9±4.9 |
0.009 |
BUN,(mmol/L) |
5.98±2.69 |
6.04±2.90 |
0.441 |
Serum creatinine,(μmol/L) |
87.5±49.4 |
92.4±28.3 |
0.154 |
Uric acid,(μmol/L) |
362.2±99.83 |
382.3±137.4 |
0.137 |
Cystatin,(mg/L) |
0.99±0.39 |
1.01±0.40 |
0.345 |
AST,(U/L) |
36.6 (21.5-146.9) |
78 (23.9-212.0) |
0.324 |
TBIL,(μmol/L) |
10.3±5.89 |
11.4±7.36 |
0.104 |
Potassium,(mmol/L) |
3.88±0.53 |
3.95±0.62 |
0.186 |
Calcium;,(mmol/L) |
2.21±0.20 |
2.18±0.18 |
0.241 |
Phosphorus,(mmol/L) |
1.06±0.34 |
1.08±0.32 |
0.386 |
Glucose,(mmol/L) |
7.82±4.80 |
9.29±6.76 |
0.025 |
CHOL,(mmol/L) |
5.38±1.28 |
5.44±1.51 |
0.383 |
Triglyceride,(mmol/L) |
1.95±1.48 |
1.73±1.04 |
0.140 |
LDL-C,(mmol/L) |
3.26±1.02 |
3.20±1.07 |
0.331 |
NT-proBNP,(pg/ml) |
176 (70.6-504) |
275 (85.7-580) |
0.017 |
eGFR(simplified MDRD formula),(ml/min/1.73m²) |
89.8±33.9 |
79.0±24.5 |
0.002 |
CIN:contrast-induced nephropathy; BMI:body mass index;BUN:Blood urea nitrogen; AST:aspartate aminotransferase;TBIL:total bilirubin;CHOL:total cholesterol; LDL-C:low density lipoprotein cholesterin; NT-proBNP:N-terminal pro brain natriuretic peptide; eGFR:glomerular filtration rate; simplified MDRD formula:eGFR=186×(Scr)-1.154×(Age)-0.203×(0.742 If Female).